Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Executive Summary
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
You may also be interested in...
Gilead Avoids $2.5bn Jury Verdict As Judge Rules Merck's Hep C Patent Is Invalid
Merck to appeal decision after district court says Gilead's discovery of sofosbuvir was 'neither routine nor simple.'
After Hep C Patent Battle, Gilead Faces ViiV Suit Over Its New HIV Drug
Complaint says similarities between Gilead's Biktarvy and ViiV's dolutegravir suggest Gilead copied ViiV's drug.
‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Regeneron and Sanofi have opportunity to appeal or to reach resolution with Amgen after district judge delays imposition of permanent injunction for 30 days in PCSK9 patent case.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: